Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1964 2
1968 1
1971 1
1972 2
1973 1
1976 1
2000 1
2001 4
2002 4
2003 2
2004 5
2005 6
2006 3
2007 6
2008 13
2009 7
2010 7
2011 10
2012 11
2013 2
2014 6
2015 10
2016 6
2017 8
2018 15
2019 10
2020 15
2021 21
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

175 results
Results by year
Filters applied: . Clear all
Page 1
Coxsackievirus B3-Its Potential as an Oncolytic Virus.
Geisler A, Hazini A, Heimann L, Kurreck J, Fechner H. Geisler A, et al. Viruses. 2021 Apr 21;13(5):718. doi: 10.3390/v13050718. Viruses. 2021. PMID: 33919076 Free PMC article. Review.
Oncolytic virotherapy represents one of the most advanced strategies to treat otherwise untreatable types of cancer. ...Its entry receptor, the coxsackievirus and adenovirus receptor (CAR), and heparan sulfate, which is used for cellular entry by some CVB3 variants,
Oncolytic virotherapy represents one of the most advanced strategies to treat otherwise untreatable types of cancer. ...Its entry rec
[Oncolytic coxsackievirus therapy as an immunostimulator].
Miyamoto S, Sagara M, Kohara H, Tani K. Miyamoto S, et al. Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977. Rinsho Ketsueki. 2017. PMID: 28883283 Review. Japanese.
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better understand its pathogenicity. In particular, coxsackievirus A21 (CVA21) is a promising candidate for oncolytic virotherapy, and thus …
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better underst …
The Oncolytic Virus in Cancer Diagnosis and Treatment.
Cao GD, He XB, Sun Q, Chen S, Wan K, Xu X, Feng X, Li PP, Chen B, Xiong MM. Cao GD, et al. Front Oncol. 2020 Sep 9;10:1786. doi: 10.3389/fonc.2020.01786. eCollection 2020. Front Oncol. 2020. PMID: 33014876 Free PMC article. Review.
There have been many kinds of oncolytic viruses, such as herpes simplex virus, adenovirus, and Coxsackievirus. Moreover, they have different clinical applications in cancer treatment. This review focused on the clinical application of oncolytic virus and pred …
There have been many kinds of oncolytic viruses, such as herpes simplex virus, adenovirus, and Coxsackievirus. Moreover, they …
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, Spitler LE, Zhou K, Bommareddy PK, Grose M, Wang M, Wu C, Kaufman HL. Andtbacka RHI, et al. J Clin Oncol. 2021 Dec 1;39(34):3829-3838. doi: 10.1200/JCO.20.03246. Epub 2021 Aug 31. J Clin Oncol. 2021. PMID: 34464163 Clinical Trial.
PURPOSE: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. ...
PURPOSE: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melano …
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.
Liu H, Luo H. Liu H, et al. Viruses. 2021 Jun 5;13(6):1082. doi: 10.3390/v13061082. Viruses. 2021. PMID: 34198859 Free PMC article.
Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent years. CVBs are a group of small, non-enveloped, single-stranded, positive-sense RNA viruses, belonging to species human Enterovirus B in the genus Entero
Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent years. CVBs are a group …
Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
Sagara M, Miyamoto S, Itoh S, Soda Y, Tani K. Sagara M, et al. Anticancer Res. 2021 Jan;41(1):81-89. doi: 10.21873/anticanres.14753. Anticancer Res. 2021. PMID: 33419801
MATERIALS AND METHODS: We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated that miRNA target sequence insertion into CVB3 reduced its pathogenicity, retaining its original oncolytic activity. ...Importantly, mi …
MATERIALS AND METHODS: We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated th …
Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
Burnett WJ, Burnett DM, Parkman G, Ramstead A, Contreras N, Gravley W, Holmen SL, Williams MA, VanBrocklin MW. Burnett WJ, et al. Cancers (Basel). 2021 Sep 4;13(17):4462. doi: 10.3390/cancers13174462. Cancers (Basel). 2021. PMID: 34503272 Free PMC article.
Oncolytic viruses (OVs) are being developed as a type of immunotherapy and have demonstrated durable tumor responses and clinical efficacy. One such OV, Coxsackievirus A21 (CVA21), exhibited therapeutic efficacy in early phase clinical trials, demonstrating the abil
Oncolytic viruses (OVs) are being developed as a type of immunotherapy and have demonstrated durable tumor responses and clinical eff
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma.
Deng H, Liu H, de Silva T, Xue Y, Mohamud Y, Ng CS, Qu J, Zhang J, Jia WWG, Lockwood WW, Luo H. Deng H, et al. Mol Ther Oncolytics. 2019 Jul 23;14:266-278. doi: 10.1016/j.omto.2019.07.003. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31463367 Free PMC article.
KRAS mutant (KRAS (mut) ) lung adenocarcinoma is a refractory cancer without available targeted therapy. The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of KRAS (mut) lung adenocarcinoma. .. …
KRAS mutant (KRAS (mut) ) lung adenocarcinoma is a refractory cancer without available targeted therapy. The current study explored the poss …
175 results